Transcriptional expression analysis of survivin splice variants reveals differential expression of survivin-3α in breast cancer

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 4, 2013, Pages 314-320

  Moniri Javadhesari, Solmaz ^a   Gharechahi, Javad ^b,c   Hosseinpour Feizi, Mohammad Ali ^d   Montazeri, Vahid ^d   Halimi, Monireh ^d  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

^d UNIVERSITY OF TABRIZ   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVIN; SURVIVIN 3 ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION SYSTEM; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE;

ADOLESCENT; ADULT; AGED; ALTERNATIVE SPLICING; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84875640838     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0411     Document Type: Article

References (43)

1. Al-Joudi FS, Iskandar ZA, Hasnan J, et al. (2007) Expression of survivin and its clinicopathological correlations in invasive ductal carcinoma of the breast. Singapore Med J 48: 607-614.
2. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921.
3. Badran A, Yoshida A, Ishikawa K, et al. (2004) Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 314:902-907.
4. Caldas H, Honsey L, Altura R (2005a) Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 4:11.
5. Caldas H, Jiang Y, Holloway MP, et al. (2005b) Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24:1994-2007.
6. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930-942.
7. Gast M-CW, Schellens JHM, Beijnen JH (2009) Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat 116:17-29.
8. Guney N, Soydine H, Derin D, et al. (2006) Serum and urine survivin levels in breast cancer. Med Oncol 23:335-339.
9. Kawasaki H, Altieri DC, Lu CD, et al. (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071-5074.
10. Kennedy SM, O'Driscoll L, Purcell R, et al. (2003) Prognostic importance of survivin in breast cancer. Br J Cancer 88:1077- 1083.
11. Lester J (2007) Breast cancer in 2007: incidence, risk assessment, and risk reduction strategies. Clin J Oncol Nurs 11:619-622.
12. Li F (2005) Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92:212-216.
13. Li F, Ling X (2006) Survivin study: an update of 'What is the next wave?'. J Cell Physiol 208:476-486.
14. Mahotka C, Wenzel M, Springer E, et al. (1999) SurvivindeltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59:6097-6102.
15. Malcles MH, Wang HW, Koumi A, et al. (2007) Characterisation of the anti-apoptotic function of survivin-DeltaEx3 during TNFalpha-mediated cell death. Br J Cancer 96: 1659-1666.
16. McCabe ML, Dlamini Z (2005) The molecular mechanisms of oesophageal cancer. Int Immunopharmacol 5:1113-1130.
17. Mola G, Vela E, Fernández-Figueras MT, et al. (2007) Exonization of Alu-generated splice variants in the survivin gene of human and non-human primates. J Mol Biol 366:1055-1063.
18. Monzo M, Rosell R, Felip E, et al. (1999) A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17:2100- 2104.
19. Nakano J, Huang C, Liu D, et al. (2008) The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers. Br J Cancer 98:1109-1117.
20. Nasu S, Yagihashi A, Izawa A, et al. (2002) Survivin mRNA expression in patients with breast cancer. Anticancer Res 22:1839-1843.
21. Noton EA, Colnaghi R, Tate S, et al. (2006) Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 281: 1286-1295.
22. Nouraee N, Mowla SJ, Ozhand A, et al. (2009) Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker. Urol J 6:101-108.
23. O'Driscoll L, Linehan R, S MK, et al. (2003) Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin- 3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Lett 201: 225-236.
24. Ouhtit A, Matrougui K, Bengrine A, et al. (2007) Survivin is not only a death encounter but also a survival protein for invading tumor cells. Front Biosci 12:1260-1270.
25. Pavlidou A, Dalamaga M, Kroupis C, et al. (2011) Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR. World J Gastroenterol 17:1614-1621.
26. Reis-Filho JS, Lakhani SR (2003) The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res 5:313-319.
27. Ryan B, O'Donovan N, Browne B, et al. (2005) Expression of survivin and its splice variants survivin-2B and survivin- DeltaEx3 in breast cancer. Br J Cancer 92:120-124.
28. Ryan BM, Konecny GE, Kahlert S, et al. (2006) Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17:597-604.
29. Sah NK, Khan Z, Khan GJ, et al. (2006) Structural, functional and therapeutic biology of survivin. Cancer Lett 244:164-171.
30. Shin S, Sung BJ, Cho YS, et al. (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and - 7. Biochemistry 40:1117-1123.
31. Sohn DM, Kim SY, Baek MJ, et al. (2006) Expression of survivin and clinical correlation in patients with breast cancer. Biomed Pharmacother 60:289-292.
32. Span P, Tjan-Heijnen V, Manders P, et al. (2006a) High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer. Breast Cancer Res Treat 98:223-230.
33. Span PN, Sweep FC, Wiegerinck ET, et al. (2004) Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 50:1986-1993.
34. Span PN, Tjan-Heijnen VCG, Heuvel JJTM, et al. (2006b) Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin Chem 52:1693-1700.
35. Suzuki A, Hayashida M, Ito T, et al. (2000) Survivin initiates cell Cycle entry by the competitive interaction with cdk4/p16 (ink4a) and cdk2/cyclin e complex activation. Oncogene 19:3225-3234.
36. Vegran F, Boidot R, Oudin C, et al. (2005) Distinct expression of survivin splice variants in breast carcinomas. Int J Oncol 27:1151-1157.
37. Vegran F, Boidot R, Oudin C, et al. (2007) Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 26:290-297.
38. Wagner M, Schmelz K, Wuchter C, et al. (2006) In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer 119: 1291-1297.
39. Wajapeyee N, Britto R, Ravishankar HM, et al. (2006) Apoptosis induction by activator protein 2alpha involves transcriptional repression of Bcl-2. J Biol Chem 281:16207-16219.
40. Yagihashi A, Ohmura T, Asanuma K, et al. (2005) Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta 362:125-130.
41. Yamada Y, Kuroiwa T, Nakagawa T, et al. (2003) Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 99:738-745.
42. Zaffaroni N, Pennati M, Daidone MG (2005) Survivin as a target for new anticancer interventions. J Cell Mol Med 9:360-372.
43. Zhang SQ, Qiang SY, Yang WB, et al. (2004) Expression of survivin in different stages of carcinogenesis and progression of breast cancer. Ai Zheng 23:697-700.